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Background: Currently, large prostate size (>80 mL) of benign prostatic hyperplasia (BPH) still pose technical
challenges for surgical treatment. This prospective study was designed to explore the safety and efficacy of
prostatic arterial embolization (PAE) as an alternative treatment for patients with lower urinary tract symptoms
(LUTS) due to largeBPH.
Methods: A total of 117 patients with prostates >80 mL were included in the study; all were failure of medical
treatment and unsuited for surgery. PAE was performed using combination of 50-μm and 100-μm particles in size,
under local anaesthesia by a unilateral femoral approach. Clinical follow-up was performed using the international
prostate symptoms score (IPSS), quality of life (QoL), peak urinary flow (Qmax), post-void residual volume (PVR),
international index of erectile function short form (IIEF-5), prostatic specific antigen (PSA) and prostatic volume (PV)
measured by magnetic resonance (MR) imaging, at 1, 3, 6 and every 6 months thereafter.
Results: The prostatic artery origins in this study population were different from previously published results.
PAE was technically successful in 109 of 117 patients (93.2%). Follow-up data were available for the 105 patients
with a mean follow-up of 24 months. The clinical improvements in IPSS, QoL, Qmax, PVR, and PV at 1, 3, 6, 12, and
24 months was 94.3%, 94.3%, 93.3%, 92.6%, and 91.7%, respectively. The mean IPSS (pre-PAE vs post-PAE 26.0 vs 9.0;
P < .0.01), the mean QoL (5.0 vs 3.0; P < 0.01), the mean Qmax (8.5 vs 14.5; P < 0.01), the mean PVR (125.0 vs 40.0;
P < 0.01), and PV (118.0 vs 69.0, with a mean reduction of 41.5%; P < 0.01 ) at 24-month after PAE were significantly
different with respect to baseline. The mean IIEF-5 was not statistically different from baseline. No major complications
were noted.
Conclusions: PAE is a safe and effective treatment method for patients with LUTS due to large volume BPH. PAE may
play an important role in patients in whom medical therapy has failed, who are not candidates for open surgery or
TURP or refuse any surgical treatment.
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Table 1 Pre-PAE baseline data (N = 117)
Characteristics Values Mean ± SD Range
Age (year) 71.5 ± 13.5 57.0–87.0
IPSS (point) 26.0 ± 5.5 21.0-35.0
QoL score 5.0 ± 1.0 4.0-6.0
PV (mL) 118.0 ± 35.0 86.0-164.0
PSA (ng/mL) 3.9 ± 3.0 1.0-7.2
Qmax (mL/s) 8.5 ± 2.0 5.0-10.0
PVR (mL) 125.0 ± 50.0 85.0-180.0
IIEF-5 (point) 11.0 ± 6.5 5.0-17.0
International Index of Erectile Function short form = IIEF-5, IPSS = International
Prostate Symptom Score, PAE = prostaic arterial embolization, PSA = prostatic
specific antigen, PV = prostatic volume, PVR = postvoid residual urine,
Qmax=peak urinary flow rate, QoL = quality of life.
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Lower urinary tract symptoms (LUTS) are common com-
plaints resulting from benign prostatic hyperplasia (BPH),
is one of the most common diseases of aging men [1,2].
LUTS can reduce quality of life by impeding normal activ-
ities and causing complications such as acute urinary
retention or urinary tract infection. The indication for
treatment depends on the severity and bother of urinary
symptoms. Treatment options include medical treatment,
minimally invasive management, and surgical therapies.
Although both medical and surgical therapies for sypto-
matic BPH are effective, they are associated with significant
morbidity rates and some degree of sexual dysfunction
[3,4]. In addition, patients with LUTS due to BPH are often
elderly and some patients may have severe comorbidities.
Because of the increasing operative risk of undergoing
transurethral resection of the prostate (TURP) or open
surgery for these patients, especially in patients with large-
volume BPH (>80 mL) [5,6], non-surgical treatment alter-
natives are required to meet their needs. Several minimally
invasive treatments were originally conceived as an attempt
to offer equivalent efficacy as operative therapy but without
the burden and risk of operative morbidity [7,8]. Therefore,
the development of new minimally invasive modalities for
treatment of BPH has constituted an interesting field of
research.
Recently, prostatic artery embolisation (PAE) for BPH has
been shown to be a safe and effective procedure that im-
proves lower urinary tract symptoms related to BPH and is
associated with a decrease in prostate volume [9-11]. How-
ever, the rate of clinical failure after PAE was relatively high.
As many as 25% of patients may not show a significant re-
duction in the international prostate symptoms score (IPSS)
or improvement in peak flow rate (Qmax). In addition, the
average of reduction rate in the prostatic volume after PAE
varies from 20% to 32% [9-12]. One component of PAE
where best practice remains to be defined is the choice of
embolic agent size. In theory, embolization with larger par-
ticles (ie, >200 μm), as previously reported results [10,11],
may not a optimal size for PAE because of early proxi-
mal occlusion. We assumed that smaller-size particles
(<100 μm) may induce greater ischemia with a more distal
penetration into the prostate, and hence lead to a better
clinical outcome. In the present study, we designed to in-
vestigate the safety and efficacy of PAE with combined
polyvinyl alcohol particles (PVA) 50-μm and 100-μm in size
as a primary treatment for patients with LUTS due to




This prospective study was approved by the hospital re-
view boards of Chinese Peoples Liberation Army GeneralHospital, and has been performed in accordance with
the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments. Written informed
consent was obtained from all the patients for the study.
From February 2009 to July 2013, a total of 117 patients
(age range, 57–87 years; mean, 71.5 years) diagnosed with
severe LUTS due to large-volume BPH (>80 mL) that was
refractory to medical treatment underwent PAE. The base
line data of these patients were provided in Table 1.
Inclusion criteria included men older than 50 years
with a diagnosis of severe LUTS (International Prostate
Symptom Score [IPSS] >18 points, quality of life [QoL]
score >3, Qmax <12 mL/sec) due to BPH refractory to
medical treatment for at least 6 months (alpha-1-adrener-
gic receptor antagonist or/and 5-alpha-reductase inhibi-
tor) and a prostatic volume (PV) >80 mL (86-164 mL).
The patient selection was achieved in a multidisciplinary
manner in conjunction with urologists and interventional
radiologists. All patients were assessed by an urologist
and anesthesiologist as being unsuited for surgery owing
to pulmonary disease (chronic obstructive pulmonary dis-
ease [COPD] in 33 patients) and cardiovascular diseases
on antiplatelet therapy (coronary artery stent placement in
57, coronary bypass in 14 and cardiac valve replacement
in 3 patients). Fifteen patients underwent transrectal US-
guided prostate biopsy due to a PSA level >4.0 ng/mL
with negative results for malignancy. Exclusion criteria
included malignancy, large bladder diverticula (>5 cm),
large bladder stones (>2 cm), chronic renal failure, active
urinary tract infection, neurogenic bladder and detrusor
failure, urethral stricture, and unregulated coagulation
parameters.
Patient evaluation
Efficacy variables of IPSS, QoL score (scored as de-
lighted = 0, pleased = 1, mostly satisfied = 2, mixed-about
equally satisfied and dissatisfied = 3, mostly dissatisfied =
4, unhappy = 5, and terrible =6), the International Index
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void residual volume (PVR), and PV were assessed
before PAE and at 1, 3, 6 and every 6 months after the
procedure. Serum prostatic specific antigen (PSA) was
assessed before PAE and at 24 hours, 1 week, 1, 3, 6 and
every 6 months after the procedure. The PV was mea-
sured by magnetic resonance (MR) imaging. The MR
imaging protocol for all examinations was the same, in-
cluding axial and sagittal T2-weighted and non–contrast-
enhanced and contrast-enhanced T1-weighted pulse
sequences, and a 1.5-T magnet was used with a phased-
array 12-channel body coil (GE Healthcare, Milwaukee,
Wisconsin). The volume of prostate was determined
using the standard ellipsoid formula: length × width ×
height × 0.52. All MR images were assessed independ-
ently by two radiologists who were unaware of the
outcomes of PAE, and disparate measurements were
resolved by consensus.
Embolization technique
Patients stopped taking all prostatic medications 3 days
before embolization. After undergoing successful PAE,
all prostatic medications were stopped during the entire
follow-up period if there was consistent clinical im-
provement. Patients started an acid-suppressing drug
(omeprazole 20 mg, AstraZeneca Pharmaceutical Co.
Ltd., China, once daily), an anti-inflammatory (naproxen
750 mg, Guangzhou Baiyun Mountain Pharmaceutical
Co. Ltd., China, twice daily) and an antibiotic (ciproflox-
acin, 500 mg, Guangzhou Xin Pharmaceutical Co. Ltd.,
China, twice daily) 1 day before the procedure and con-
tinued for 7 days following PAE. During PAE, we did not
us the analgesic drugs routinely because all the patients
were well tolerated to the procedures.
Angiography
Patients underwent angiography and PAE in a therapeutic
angiography unit equipped with a digital flat-panel detector
system (INNOVA 4100 IQ; GE Healthcare, Milwaukee,
Wis, USA) with nonionic contrast medium (Visipaque 320
mgI/mL; GE Healthcare). Embolization was performed
with a unilateral femoral approach in all patients. After
local anesthesia was achieved, the femoral artery was can-
nulated using a 4-Fr vascular sheath (Radifocus, Terumo,
Japan) with Seldinger’s technique.
Initial pelvic angiography was performed with a 4-Fr
pigtail type catheter (Cordis, USA) to evaluate iliac
vessels. Selective digital subtraction angiography (DSA)
was performed with a 4-Fr Simmons I catheter (Cordis,
USA) to evaluate the hypogastric and prostatic arteries
(PAs) by using the ipsilateral anterior oblique projection
of 30o. The PAs were identified with DSA and Cone-
beam computed tomography (CB-CT), and selectively
catheterized with a coaxial 2.7-F microcatheter (Progreat2.7; Terumo, Tokyo, Japan). Selective PA angiography
before embolization was performed (3–5 mL contrast
medium at 0.5-1 mL/s) in neutral and ipsilateral anterior
oblique projections (35o) to ensure that the tip of the
microcatheter was inside or at the ostium of the pros-
tatic arteries. CB-CT was performed with a 3–5-second
delay after injection of 4–6 mL contrast medium at 0.5-
1 mL/s to evaluate for sites of nontarget embolization.
The origin of the prostatic arteries, revealed by the
DSA, rotational angiography (images from a rotational
scan acquired with a C-arm equipped with a flat panel
detector) and Cone-beam CT, was assessed independ-
ently by two interventional radiologists with more than
10 years of experience; and the disparate findings were
resolved by consensus.Embolization
We started PAE with smaller PVA particles (47 ~ 90-μm,
mean 50-μm; Polyvinyl alcohol foam embolization parti-
cles, PVA, Cook Incorporated, Bloomington, IN, USA))
for the distal or intra-prostate embolization; when reach-
ing near stasis in the intra-prostate arterial branchese,
we switched to larger PVA particles (90 ~ 180-μm, mean
100-μm; PVA, Cook Incorporated, Bloomington, IN, USA)
for the proximal of the prostatic arterial embolization. This
technique was modified from the suggestion by Bilhim T
et al. [13]. We believe that using the smaller-sized particles
firstly is essential to avoid early proximal occlusion of the
prostatic arteries and to achieve the goal of diffuse gland
parenchymal ischemia.
Each vial of PVA (1 mL) was diluted in a 40-mL solution
of nonionic contrast medium (iodixanol 320 mgI/mL; Vis-
ipaque; GE Healthcare). The particles were slowly injected
through a 2-mL syringe under fluoroscopic control. Before
embolization, vasodilator with nitroglycerin (200-300 μg)
was used intra-arterially through the microcatheter to
prevent vasospasm and to increase artery size to facili-
tate super-selective catheterization. The end point of
embolization was near stasis; after it was achieved, a wait-
ing time of 4-5 min followed for the particles to be redis-
tributed in the feeding vessels; and then more embolic
material was injected until complete stasis of the feeding
artery was seen fluoroscopically. After PAE, angiography
was performed using the power injector, with the 4-F
catheter at the anterior branch of the internal iliac artery
to check for any further blood supply to the prostate.
Embolization was then performed on the contralateral
side by using the same technique.Post-procedural management
The patients stayed in the hospital for 1-6 days for ob-
servation. The patients were monitored for adverse
effects. Appropriate hydration was administered 2 to
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given to prevent infection as described before.
Outcome measures
Technical success was defined as unilateral or bilateral
PAE, as successful embolization of all angiographically
and/or CBCT-visible arterial supply to the prostate. Pri-
mary end points were the reduction of 7 points of the
IPSS (or at least reduction of 25 % of the total score) and
the increase of Qmax (>3 mL/sec) at 24-month after PAE.
Secondary end points were the reduction of PV, PVR, and
QoL at 24 months after PAE. Clinical failure after PAE
was defined when one of the following criteria was met:
IPSS ≥ 20, QoL ≥ 4, Qmax improvement <3 mL/s.
Postembolization symptoms and complications were reg-
istered and classified according to the quality improvement
guidelines for percutaneous transcatheter embolization
[14]. Complications were considered minor if they could
be addressed by ambulatory medical treatment and major
if they resulted in prolonged hospitalization, hospital re-
admission, or required surgery.
Statistical analysis
The study’s quantitative variables were expressed as mean
values, standard deviation, and minimum and maximum
values, whereas the qualitative variables were expressed as
numbers and percentages. A Student t test for paired sam-
ples was used when appropriate. A P value of 0.05 or
lower was considered to indicate statistical significance.
Statistical analysis was performed using SPSS 16.0 soft-
ware for Windows (Chicago, Illinois).
Results
PAE was technically successful in 109 of 117 patients
(93.2%). Technical failure was seen in 8 patients (6.8%):
the embolization was impossible owing to severe tortu-
osity and atherosclerotic changes of the iliac arteries in 6
patients, none of the prostatic arteries were revealed in 2
patients. Bilateral PAE was performed in 101 (92.7%) pa-
tients; the remaining 8 (7.3%) patients underwent unilat-
eral PAE due to severe atherosclerotic stenosis of an
unilateral PA. Mean procedural time was 105 min (range
65–180 min) with a mean fluoroscopy time of 30.0 min
(range 20–45 min).
Based on the analysis of selective DSA, rotational angi-
ography, and CB-CT of the internal iliac arteries, it was
possible to identify the number of independent PAs and
their origin in 109 patients with 218 pelvic sides. There
was one PA in 95.0% of the pelvic sides (207/218) and
two independent PAs in 5.1% (11/218). The most fre-
quent PA origin was the gluteal-pudendal trunk (39.5%;
86/218; Figure 1). Other common origins were the su-
perior vesical artery (31.7%; 69/219; Figure 2), the mid-
dle third of internal pudendal artery (27.5%; 60/218;Figure 3). Three PAs (1.4%) arise from the middle rectal
artery (Table 2).
Follow-up data were available for the 105 patients,
who were observed for a mean of 24 months (range 17–
36 months). Four patients were lost to follow-up. The
proportion of patients who demonstrated clinical success
at 1, 3, 6, 12, and 24 months was 94.3% (99 of 105 pa-
tients), 94.3% (99/105 patients), 93.3% (98 of 105 pa-
tients), 92.6% (87 of 94 patients), and 91.7% (77 of 84
patients), respectively. As shown in Table 3, the LUTS of
the patients showed significant improvements. Signifi-
cant infarcts (mean 60%, range 55 %-90 %) were seen in
all patients with clinical success as measured by MRI at
1-month after PAE, exclusively in the prostatic central
zone; the infarct areas were reduced progressively in
size. At 6-12 months after PAE, the infarcts could not be
detected clearly in the majority of patients, resulting
from the netrotic tissue absorption (Figures 4 and 5).
At 24-month follow-up of these 84 patients, the mean
IPSS decreased from 26.0 ± 5.5 points to 9.0 ± 5.5 points
(P < 0.01), mean QoL decreased from 5.0 ± 1.0 points to
3.0 ± 1.0 points (P < 0.01), mean Qmax increased from
8.5 ± 2.0 to 14.5 ± 3.5 mL/s (P < 0.01), mean PVR de-
creased from 125.0 ± 50.0 mL to 40.0 ± 15.0 mL (P < 0.01),
and mean PV decreased from 118.0 ± 35.0 mL to 69.0 ±
18.0 mL (with a mean reduction of 41.5%, P < 0.01). Sixty-
two patients were followed more than 24 months and
these changes were sustained throughout the observation
period. No significant differences (P = 0.6) were observed
in IIEF-5 scores during the follow-up period compared
with preoperative data.
The serum total PSA values before and after PAE were
provided in Table 4. At 24 h after embolization, the mean
serum total PSA increased from 4.00 ± 2.50 ng/mL to
87.50 ± 45.00 ng/mL (with s mean of 21.9 times relative to
the mean baseline values; P < 0.01). By 1 week after
embolization, mean PSA dropped to 30.5 ± 20.0 ng/mL
(mean, 7.6 times; P < 0.01). By 1 month after embolization,
mean PSA dropped to the baseline values (P = 0.6); by
3-month and 6-month of follow-up, the mean PSA was
statistically significantly lower than at baseline (P < 0.05),
and was almost sustained over time.
Poor outcome after PAE was observed in 7 (8.3%) pa-
tients at 24 months after PAE: unilateral PAE in 6 pa-
tients and bilateral PAE in one patient. The PAS values
in the 7 patients were increased by 4.9-8.5 times (mean,
7.0 times) relative to their mean baseline values at 24 h
after embolization. The prostate infarction rate detected
by MRI at 1 month after PAE in the 7 patients was 10%-
25%; the PV reduction rate at 3-month follow-up was
10%-17% (mean, 15%). The clinical failure had direct re-
lationship with the PAS values at 24 h after PAE, the
prostate infarction rate at 1 month after PAE, and the
PV reduction rate at 3-month follow-up.
Figure 1 Prostatic artery arise from the gluteal-pudendal trunk. Images from a patient with significant lower urinary tract symptoms due to
benign prostatic hyperplasia (92 mL) underwent bilateral PAE. a. Digital subtraction angiography (DSA) after selective catheterization of the
anterior division of the left internal iliac artery with ipsilateral oblique view demonstrated the left prostatic artery (straight arrow) arising from
gluteal-pudendal trunk; the curved arrow indicates the left internal pudendal artery; and the asterisk indicates the contrast staining in the left
prostate lobe. b. Cone-beam CT image with coronal view after selective catheterization of the anterior division of the left internal iliac artery
demonstrates the left prostatic artery (straight arrow) and the left internal pudendal artery (curved arrow). The asterisk indicates the contrast
staining in the left prostate lobe.
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minor complications (Table 5), urethral burning oc-
curred in 19 (17.4%) patients, transient hematuria oc-
curred in 11 (10.9%) patients, transient hemospermia
occurred in 9 (8.1%) patients, transient rectal bleedingFigure 2 Prostatic artery arise from the superior vesical artery. Image from
hyperplasia (121 mL) underwent PAE. a. Digital subtraction angiography (DSA
oblique view demonstrates the left prostatic artery (straight arrow) and the su
pattern of intra-prostate arteriola. b. Cone-beam CT image with coronal view
iliac artery demonstrates the left prostatic artery (straight arrow) and the supe
pattern of intra-prostate arteriola.occurred in 8 (7.34%) patients, and small inguinal
hematoma at the punctured site occurred in 3 (2.8%) pa-
tients. These patients with small amount of rectal bleed-
ing may be attributed to ischemic rectal complication,
resulted as the rectal nontarget embolization. All thesea patient with lower urinary tract symptoms due to benign prostatic
) of the anterior division of the left internal iliac artery with ipsilateral
perior vesical artery (curved arrow). The asterisk indicates the corkscrew
after selective catheterization of the anterior division of the left internal
rior vesical artery (curved arrow). The asterisk indicates the corkscrew
Figures 3 Prostatic artery arise from the internal pudendal artery. Images from a patient with severe lower urinary tract symptoms due to benign
prostatic hyperplasia (117 mL) underwent PAE. a. Digital subtraction angiography (DSA) of the anterior division of the left internal iliac artery
with ipsilateral oblique view demonstrates the left prostatic artery (straight arrow) and the left internal pudendal artery (arrowhead). The asterisk
indicates the contrast staining in the left prostate lobe. b. Cone-beam CT image with coronal view after selective catheterization of the anterior
division of the left internal iliac artery demonstrates the left prostatic artery (straight arrow) and the left internal pudendal artery (arrowhead). The
curved arrow indicates the inferior vesical artery, which is difficult to identifying on the DSA. The asterisk indicates the contrast staining in the left
prostate lobe.
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Thirty-one patients (28.4%) experienced acute urinary
retention at 1-3 days after PAE; for relief, a temporary
bladder catheter was placed at the time for 3-6 days and
the patients were able to void spontaneously before dis-
charge. There were no incidences of ejaculatory disor-
ders post-procedure. No other minor complications
were observed.
Discussion
The surgical management of patients with prostate vol-
umes >80 mL causing LUTS secondary to BPH presents
a challenge [15]. TURP has been the ‘gold standard’ sur-
gical procedure during the last 30 years, but its role in
treating patients with prostate volumes >80 mL is lim-
ited, mainly because of intra-operative and postoperative
morbidities (e.g., intraoperative and postoperative bleed-
ing, postoperative hyponatremia, and urethral stricture)
[16,17]. Despite the more recent development of new
techniques such as endoscopic laser enucleation, plasmaTable 2 Prostatic artery origin: 109 patients (218 pelvic
sides)
PA orign Incidence
Gluteal-pudendal trunk 86 (39.5%)
Superior vesical artery 69 (31.7%)
Internal pudendal artery 60 (27.5%)
Middle rectal artery 3 (1.4%)enucleation, and laparoscopic adenomectomy, in terms
of efficacy, open prostatectomy (OP) is still considered
the “gold standard” for the surgical treatment of BPH in
patients with prostates > 80 mL [1,2]. However, OP is as-
sociated with a high morbidity rate, considerable blood
loss, prolongedrecovery time, and heavy patient burden
[2]. Serretta et al. [18] reported 8.2% blood transfusion
in a large Italian series of open prostatectomy for large
prostates. Gratzke et al. [19] performed open surgery on
902 BPH patients with an average prostate volume of
96.3 ± 37.4 mL and found that the total incidence of
postoperative complications reached 17.3%. Thus, the
new treatment options are necessary to meet this chal-
lenge. Recently, PAE is emerging and is a promising
minimally invasive therapy that improves lower urinary
tract symptoms related to BPH and is associated with a
decrease in PV [9-11].
Our study demonstrates that PAE could be used safely
and effectively as a alternative treatment for BPH in pa-
tients with large volume BPH. Consistent with the litera-
tures [9-11,20], our experience showed that PAE is a safe
procedure, even in patients who were unsuited for sur-
gery, without significant increases in morbidity or mortal-
ity. In the studies by Carnevale FC et al. [10], Bagla S et al.
[20], and Pisco JM et al. [21], the mean prostatic volume
before PAE was 69.7 mL (range 43.5-92 mL), 64 mL, and
83.5 mL (range 24-269 mL), respectively. In our study the
mean prostate volume before PAE (118 mL, range 86-
164 mL) was larger than that of the previous studies.
Table 3 Clinical values over time of response variables after PAE
Variable 1 Mo (n = 105) 3 Mo (n = 105) 6 Mo (n = 105) 12 Mo (n = 94) 24 Mo (n = 84)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD P Values
Age(year) 71.5 ± 12.5 71.5 ± 12.5 71.5 ± 12.5 72.5 ± 11.5 70.5 ± 11.0 _
IPSS(point) 9.5 ± 5.5 8.5 ± 3.0 7.5 ± 4.0 8.0 ± 4.5 9.0 ± 5.5 <0.01
QoL score 2.5 ± 1.0 3.0 ± 0.5 3.0 ± 1.0 2.5 ± 1.5 3.0 ± 1.0 <0.01
PV (mL) 103.8 ± 30.0 72.5 ± 25.0 70.0 ± 15.0 68.5 ± 15.0 69.0 ± 18.0 <0.01
Qmax (mL/s) 14.0 ± 3.5 15.0 ± 4.5 15.5 ± 6.5 14.5 ± 5.0 14.5 ± 3.5 <0.01
PVR (mL) 45.0 ± 20.0 40.0 ± 25.0 35.0 ± 15.0 40.0 ± 20.0 40.0 ± 15.0 <0.01
IIEF-5 (point) 11.0 ± 5.0 10.0 ± 4.0 12.0 ± 3.0 13.0 ± 2.0 10.0 ± 2.5 0.6
IIEF-5 = International Index of Erectile Function short form, IPSS = International Prostate Symptom Score, PSA = prostatic specific antigen, PV = prostate volume,
PVR = postvoid residual urine, Qmax=peak urinary flow rate, QoL = quality of life.
Figures 4 Images from a patient with lower urinary tract symptoms due to large benign prostatic hyperplasia (107 mL) underwent bilateral
PAE. a. Angiography after selective catheterization of the riht prostatic artery (straight arrow) demonstrates contrast staining in the right prostate
lobe (asterisk). b. Cone-beam CT image with coronal view after super-selective catheterization of the right prostatic artery demonstrates the the
anterior-lateral prostatic branch (arrowhead), supplying to the central gland; the posterior-lateral prostatic branch (straight arrow), supplying to
the peripheral and caudal gland. The asterisk indicates the contrast staining in the right prostate lobe and the curved arrow indicates the right
internal pudendal artery. c. Angiography after super-selective catheterization of the left prostatic artery (straight arrow) demonstrates the corkscrew
pattern of intra-prostate arteriola and contrast medium staining in the left prostate lobe (asterisk). d. Cone-beam CT image with coronal view after
super-selective catheterization of the left prostatic artery (straight arrow) demonstrates contrast medium staining in the left prostate lobe (asterisk).
The curved arrow indicates a branch of superior vesical artery, usually presented with high pressure injection of contrast medium through the
anastomoses.
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Figures 5 MR Images from a patient with lower urinary tract symptoms due to large benign prostatic hyperplasia underwent bilateral PAE,
the same case as the Figure 4. a-b. Enhanced T1-weighted coronal MR images obtained before PAE shows a large benign prostatic hyperplasia
(straight arrows). c-d. Enhanced T1-weighted coronal MR images obtained at 1-month after PAE shows significantly infarct areas on the both side
of the prostate (straight arrows), with the volume reduction of 12%. e-f. Enhanced T1-weighted coronal MR images obtained at 12-month after
PAE shows the prostate volume reduction of 62%; this patient experienced marked clinical improvement during 32 months follow-up, with IPSS
improvement of 85%.
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to 24-month of follow-up (118.0 mL vs 69.0 mL, with a
mean reduction of 41.5%, P <0.01), and Qmax increased
(8.5 mL/s vs 14.5 mL/s, mean increase of 70.59%,
P <0.01). This decrease in PV and increase in Qmax was
accompanied by a significant reduction in BPH symptomburden as measured by IPSS (mean score, 26.0 at base-
line, 9.0 in follow-up; P <0.01) and a commensurate im-
provement in patient QoL (mean index, 5.0 at baseline,
3.0 in follow-up; P <0.01). Many patients with LUTS due
to large volume BPH are elderly, fragile patients with
various comorbidities and therefore unsuited for surgery
Table 4 Total serum PSA values before and after PAE
(n = 84)
Values (ng/mL, Mean ± SD) Range P Values
Pre-PAE 4.0 ± 2.5 1.2-6.5 -
24 h 87.5 ± 45.0 30.0-145.0 <0.01
1 week 30.5 ± 20.0 9.5-57.0 <0.01
1-Month 4.2 ± 2.5 1.5-6.0 0.6
3-Month 3.7 ± 1.6 0.8-4.5 0.04
6-Month 3.1 ± 1.5 1.0-4.5 0.03
12-Month 3.9 ± 2.5 0.7-4.9 0.05
18-Month 4.1 ± 1.5 1.0-4.6 0.05
24-Month 3.7 ± 1.5 1.5-4.7 0.05
PAE = prostaic arterial embolization, PSA = prostatic specific antigen.
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tial for PAE as an alternative treatment in patients with
prostates > 80 mL is significant because TURP and lap-
aroscopic prostatectomy are typically not considered for
this population [1,2].
Comprehension of the functional arterial anatomy is
crucial for an effective and a safe embolization, allowing
better results and avoiding complications from untar-
geted embolization to surrounding organs (bladder, rec-
tum, and penis) [22]. In a recent in vivo study by Bilhim
T et al. [23], the authors reported that the origin of the
prostatic artery is highly variable. PAs usually arise from
the internal pudendal artery (35%), from a common ori-
gin with the superior vesical artery (20%), from the com-
mon anterior gluteal-pudendal trunk (15%), from the
obturator artery (10%), or from a common prostato-
rectal trunk (10%). Other origins are from the inferior
gluteal artery, superior gluteal artery, or from an
accessory pudendal artery (10%). Carnevale FC et al. [10]
reported that the most common artery supplying the
prostate was the inferior vesical artery, but branches
from other arteries were also found to feed the gland. In
the present study, we used the conventional DSA, com-
bined with rotational angiography and CB-CT, for iden-
tifying the prostatic arteries and its origin; it may beTable 5 Minor complications in the first week after PAE
(n = 109)
Adverse event Number of patients (%)
Urethral burning 19 (17.4%)
Hematuria 11 (10.9%)
Hematospermia 9 (8.1%)
Rectal bleeding 8 (7.3%)
AUR 31 (28.4%)
Inguinal hematoma 3 (2.8%)
PAE = prostate arterial embolization, AUR = acute urinary retention.more accurate and more reliable than the conventional
DSA alone for evaluation the pelvic vascular anatomy
[21]. Our findings of the prostatic artery origins were
somewhat different from previously published results
[10,23]. In this study, we found that 95.0% of the internal
iliac artery had only one prostatic artery, 5.1% (11/218)
had two independent prostatic arteries, 39.5% originated
from the gluteal-pudendal trunk,31.7% originated from
the superior vesical artery (as a common pedicle with
the superior vesical artery), and 27.5% of PA originated
from the pudendal artery. Unlike reported by Bilhim T
et al. [23] and others [10,24], we did not found that the
prostatic arteries originated from the obturator artery,
inferior gluteal artery, and superior gluteal artery.
A modified embolization protocol, which developed
was based on others work [13] and our early clinical ex-
perience of PAE, was used in this study. We started
embolization with smaller-sized PVA particles (50-μm)
for the distal embolization, and ended with larger (100-
μm) for the proximal embolization. Our data showed
that the mean PV was decreased from 118.0 ± 35.0 mL
to 69.0 ± 18.0 mL (a mean reduction of 41.5%) after PAE
at 24-month follow up. The reduction rate was higher
than those of previous reports by Bagla et al. [11] with a
mean reduction of 18% and by Pisco et al. [9] with a
mean reduction of 20%. Using the “standard technique”
and 100-300 μm particles size, the infarcts have been
seen in only 70.6% of the patients with a mean infarction
rate of 30%-50% after PAE [9,25]. In the present study,
we have observed infarcts area ≥50% in all patients with
clinical success as measured by MRI. In addition, we
have observed that serum total PSA values increased sig-
nificantly at 24 h after embolization, with a mean 21.9
times relative to the mean baseline values; these also
suggested that greater prostate infarction occurred after
PAE with the smaller size particles.
It is reasonable to assume that smaller-sized particles
may induce greater ischemia with a more distal penetra-
tion into the prostate microvasculature [13], and hence
lead to a better clinical outcome. Because BPH develops
primarily in the peri-urethral region of the prostate,
therefore embolization of this part is important for im-
provement of LUTS. From previous studies [9,13], we
knew that 100-μm PVA particles could be used safely for
PAE without untargeted embolization. Anatomically, the
prostatic part of the urethra is supplied by a branch of
prostatic artery, both in dogs and in humans, with a
diameter of 40–60 μm [26]. Based on these data, parti-
cles with 50-μm in size may penetrate into the peri-
urethral region of the prostate, with a better result than
that of particles ≥100-μm in size. However, untargeted
embolization and injury of the urethral wall should be
concerned using the small sized particles. In the present
study, no major complications were observed from PAE
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comparable to previously reported results [9-11], and all
minor complications could be addressed with conserva-
tive care, showing that PAE with the combination of 50-
μm and 100-μm particles is a safe procedure.
Bilateral PAE appears to produce better results than
that of unilateral PAE. According to the reported by
Bilhim T et al. [27], good clinical outcomes and im-
provements in urodynamic data could be achieved even
in patients who underwent unilateral PAE. Another
series reported by the same authors [28] showed that
unilateral PAE might lead to moderate clinical relief with
8% PV reduction and 18% reduction in PSA. The au-
thors suggested that the anastomoses between prostatic
arteries from both pelvic sides, presented in as many as
20% of individuals, may partially explain these results
[29]. In our study, of the 8 patients with unilateral PAE,
Only two patients had clinical improvement during a
24-month follow-up. Carnevale FC et al. [30] reported
one patient had unilateral PAE with continuous prostate
reduction until 12 months follow-up (maximum of 27.8%
reduction at the 6-month follow-up) and re-growth to the
initial size at the 3-year follow-up. Therefore, the bilateral
PAs and any other prostatic branches should be embolized
to achieve optimal prostate ischemia, resulting in volume
reduction for better long-term results.
No serious complications or adverse events in the per-
formance of PAE were observed in the present series. The
incidence of minor complications (ie., transient hematuria,
hemospermia, and rectal bleeding) after PAE in the pa-
tients with large BPH was similar to those of previous re-
ports [9-12]. In comparison with others reports [9,11,21],
however, the acute urinary retention (AUR) after PAE was
relatively high (28.4%) in our series; this may explained by
the large volume BPH nature and edema in the periure-
thral prostatic tissue after embolization. For management
of AUR, a temporary bladder catheter and antibiotics
should be maintained for 1 week after PAE under the
urologist’s supervision.
There are some limitations to the present study. First,
this study was a single-center experience with limited
follow-up; however, continued follow-up is ongoing, and
longer follow-up in our patients will bring additional in-
formation in the future. Second, the present study in-
cluded only in patients with large-volume BPH and with
unsuited for surgery; further analyses are necessary to es-
tablish the role of PAE in patients who are candidates for
surgery, or the prostate volume less than 80 mL. Third,
only PVA particle was used for our procedures; further in-
vestigation concerning different type of embolic agents are
necessary. Finally, this is a non-randomised and non-
comparative study. Although the results are promising
more studies are needed, especially multicentre rando-
mised controlled trials.Conclusions
Our clinical results shows that PAE is a safe and effect-
ive treatment method for patients with severe LUTS due
to large volume BPH. PAE may play an important role
in patients in whom medical therapy has failed, who are
not candidates for open surgery or TURP or refuse any
surgical treatment. The prostatic artery origins in the
present study population were different from previously
published results. Larger case series, longer follow-up
time, and comparative studies with standard TURP or
holmium laser enucleation of the prostate (HoLEP) are
needed, not as much to evaluate safety and efficacy of
PAE, but to determine which patients should undergo
which treatment.
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